Anthem Biosciences Reports Q1 Profit Decline Amid Lower Revenue in FY 2026-27
Anthem Biosciences reported a consolidated net profit of ₹119.94 crore for Q1 of FY 2026-27, marking an 11.67% decline from the previous year. Revenue from operations fell 22.58% to ₹418.22 crore compared to the same quarter last year. Profit before tax decreased to ₹144.58 crore, while total expenses dropped to ₹298.53 crore. The CRDMO segment contributed ₹340.80 crore, and the Speciality Ingredients segment ₹77.42 crore. Employee benefit expenses increased slightly, and the company allotted over 1.67 million shares under its ESOP Scheme 2024.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (48/100). Lens Score 33/100.
Outlets measured: businessstandard, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (45–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 21 Jul, 11:25 am. Other outlets followed.